NO162368B - Grunnmasse til bruk i et legemiddelfrigivende preparat for syre-stabile polypeptider. - Google Patents

Grunnmasse til bruk i et legemiddelfrigivende preparat for syre-stabile polypeptider. Download PDF

Info

Publication number
NO162368B
NO162368B NO831413A NO831413A NO162368B NO 162368 B NO162368 B NO 162368B NO 831413 A NO831413 A NO 831413A NO 831413 A NO831413 A NO 831413A NO 162368 B NO162368 B NO 162368B
Authority
NO
Norway
Prior art keywords
alloy
temperature
approx
anodizing
color
Prior art date
Application number
NO831413A
Other languages
English (en)
Other versions
NO831413L (no
Inventor
Jeffrey Richard Churchill
Francis Gowland Hutchinson
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Plc filed Critical Ici Plc
Publication of NO831413L publication Critical patent/NO831413L/no
Priority to NO841544A priority Critical patent/NO164302C/no
Publication of NO162368B publication Critical patent/NO162368B/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Cosmetics (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Fremgangsmåte til fremstilling av aluminiumplater for fargeanodisering.
Den foreliggende oppfinnelse angår en da der bare ble fremstilt fargeløse belegg, fremgangsmåte til å behandle en alumini- Det viktigste av disse problemer er en på-umlegering på en slik måte at den blir spe- litelig reproduksjon av farger og andre sielt egnet til å få påført et gjennomfarget egenskaper som angår utseendet. En arki-(inherently coloured) anodisk oksydbelegg. tekt kan f. eks. velge farget aluminium for
Det er vel kjent å fremstille gjennom- en bygningskonstruksjon ut fra små prøve-fargede anodiske oksydbelegg på alumini- stykker, hvoretter anodiseringsbedriften um og aluminiumlegeringer. Beleggene må fremstille hundrevis av kvadratmeter fremstilles ved at aluminiumgjenstanden anodisert aluminium i form av store plater som skal anodiseres, neddykkes som anode som må svare såvel til prøvestykket som til i en elektrisk krets som omfatter anoden, en hverandre for å kunne godtas for anven-inert katode og en elektrolytt som inne- deise i konstruksjonen. Under fremstilling holder svovelsyre og en eller annen av visse av et stort antall slike gjenstander kan substituerte aromatiske sulfonsyrer. De sammensetningen av elektrolytten eller aromatiske sulfonsyrer som er spesielt an- andre prosessvariable forandre seg, og slike vendelige, er sulfosalicylsyre og sulfoftal- forandringer kan påvirke utseendet av pro-syre, selv om også andre syrer er funnet å duktet. Sett fra anodiseringsbedriftens være brukbare. Skjønt svovelsyre er det standpunkt er det imidlertid mulig å holde mest anvendelige materiale til frembrin- de variable i prosessen og sammensetningen geise av sulfationer, kan anodiseringspro- av elektrolytten konstant, selv om dette sessen utføres med sulfater av tunge me- ikke er noen enkel sak, og aktpågivenhet taller oppløst i elektrolytten istedenfor eller overfor disse detaljer kan dempe forskjel-
i tillegg til svovelsyre, og det mest vanlige lene i utseendet av produktet,
av slike sulfater er jernsulfat. Det anodiske En faktor som er utenfor anodiserings-oksydbelegg som fås ved denne fremgangs- bedriftens herredømme, er imidlertid den måte, har farger i området fra gyllent til reaksjon som en legering har på en farge-sort og kan utføres med nesten en hvilken anodiseringsbehandling, og som skyldes som helst mellomliggende tone av bronse metallurgiske overveielser. To prøvestykker eller brunt. Slike farge-anodiseringsproses- av en bestemt aluminiumlegering kan f .eks. ser har fått vid anvendelse for fremstilling na anodiske oksydbelegg som har noe for-av aluminium til byggeformål og andre skjellig farge til tross for at de er fremstilt dekorative anvendelser. ved den samme anodiseringsprosess, hvis
Fremgangsmåter til fremstilling av f-eks. en av legeringene har en sammen-gjennomfargede anodiserte aluminium- setning som med hensyn til forurensnings-gjenstander har gitt opphav til problemer nivå er forskjellig fra sammensetningen av som ikke var kjent i anodiseringsteknikken den annen legering, eller hvis to legeringer med samme sammensetning har vært ut-satt for forskjellig varmebehandling under fremstillingen. Det er f. eks. kjent at forskjeller i homogeniseringstemperaturen av valseblokkene eller forskjeller i den tid blokkene holdes på homogeniseringstemperaturen eller forskjeller i avkjølingshas-tigheten av blokkene etter homogeniserin-gen kan gi vesentlige forskjeller i fargereaksjonen når disse blokker blir valset til plater og underkastet fargeanodisering. Videre kan forskjeller med hensyn til utseendet som følge av små forskjeller i for-urensingsnivået forsterkes av variasjoner i varmebehandlingen.
Ved fremstilling av platemateriale for farge-anodisering har legeringer som i klassifiseringssystemet til «Aluminium As-sociation of America» er betegnet som 5005, vist seg å ha ønskede egenskaper med hensyn til deres evne til å gi fargede anodiske oksyder og formes til glatte plater med fysiske egenskaper som er egnet for byggeformål. Vrediene for sammensetningen av en 5005-legering ifølge «Aluminium Asso-ciation of America» er:
For de bestanddeler hvor der ikke er angitt et område, angir verdiene den mak-simalt tillatte mengde. Det er funnet at en variasjon av sammensetningen innenfor de grenser som er gitt ovenfor, ikke er tillate-lig for legeringer som anvendes for farge-anodisering, idet visse av bestanddelene medfører store forandringer i fargereaksjonen, slik at legeringer med henholdsvis det høyeste og det laveste innhold gir legeringer som når de underkastes den samme anodiseringbehandling, vil gi farger som er for ulike til å kunne aksepteres. Det er videre funnet at tilstedeværelsen av for meget av visse av de forurensende bestanddeler, f. eks. Mn, Cr, Fe og Si gjør legeringene usedvanlig følsomme med hensyn til den virkning som den forutgående varmebehandling har på fargereaksjon. Visse forurensende elementer vil således få legeringen til å reagere vesentlig annerledes på farge-anodisering hvis den er termisk behandlet på én måte enn hvis den er termisk behandlet på en annen måte.
Den foreliggende oppfinnelse omfatter at der er funnet frem til grenseverdier for sammensetningen av aluminiumlegeringer som kan anvendes til fremstilling av gjennomfargede anodiske oksydbelegg, og varmebehandlinger for slike legeringer som gir et platemateriale som ikke er følsomt hver-ken for moderate variasjoner i sammensetningen eller den forutgående varmebehandling. Den foreliggende oppfinnelse skaffer således aluminiumplater som er lette å anodisere til et utseende som kan reproduseres og forutses, og aluminiumplater hvor disse egenskaper med hensyn til anodiseringsreaksjonen foreligger i de val-sede produkter, slik at anodiseringsbedrif-ter, som vanligvis er dårlig utstyrt for ut-førelse av metallurgiske prosesser, rett og slett kan anodisere materialet i den varme-behandlede tilstand de mottar det, og stole på den reaksjon med hensyn til utseende som vil komme til syne i anodiseringspro-sessen.
Dette oppnås ved den fremgangsmåte
som er angitt i karakteristikken i påstand 1.
Ifølge oppfinnelsen fremstilles der således en legering som foruten aluminium inneholder 0,06—0,15 % silisium, 0,45— 0,65% jern, 0,03—0,10% kobber, 0—0,07% mangan, 0,7—0,9 % magnesium, 0,05— 0,10 % krom, 0—0,25 % sink og opptil ca. 0,15 % forskjellige forurensninger.
Alle de mengdeforhold som er angitt i beskrivelse og påstander er vektforhold. Den således sammensatte legering støpes til en blokk og oppvarmes til homogeniseringstemperatur, fortrinnsvis til mellom 593 og 621° C, hvor den holdes inntil det meste av dé oppløselige elementer er kommet i fast oppløsning, fortrinnsvis i et tidsrom av minst syv timer. Hensikten med denne be-handling er å skaffe en metallurgisk struk-tur hvor de primære legeringsbestanddeler
og forurensninger er jevnt fordelt og opp-løst i aluminiumet. Legeringen blir deretter
sakte avkjølt til en temperatur under 510° C, idet avkjølingen utføres med en gjen-nomsnittshastighet av 17° C pr. time eller langsommere. Etter at en temperatur av 510° C er nådd, kan blokken avkjøles til værelsetemperatur med praktisk talt en hvilken som helst hastighet, og den kan deretter overflatehøvles eller på annen måte forberedes for valsing. Før valsing til plater oppvarmes blokken påny til en temperatur av under 510° C, fortrinnsvis mellom 454 og 510° C, og holdes på denne temperatur i ca. en time. Valsing kan deretter utføres på vanlig måte for å fremstille plater av hvilken som helst ønsket tykkelse.
Det menes at et melkelignende eller matt utseende av anodiske oksydbelegg for-årsakes av partikler av utfelte legerings-elementer eller kombinasjoner av legerings-elementer. Ved vanlige varmebehandlinger hvor en legering homogeniseres og tas ut av ovnen for å avkjøles i luft, er avkjølings-hastigheten fra homogeniseringstemperaturen så høy at legeringen raskt når en temperatur hvor diffusjonen av atomer eller molekyler inne i legeringen er meget langsom. Av denne grunn vil utfellingen forekomme i form av mange små partikler, og dette store antall små partikler vil fremkomme i et senere fremstilt anodisk oksydbelegg, hvor de vil spre lyset og gi inntrykk av et matt eller melkelignende belegg. Blant de partikler som først ut-felles når temperaturen av en legering fal-ler under homogeniseringstemperaturen, er de jernholdige partikler, som vanligvis er kombinasjoner av jern med aluminium, mangan, krom og andre bestanddeler i legeringen.
Ved fremgangsmåten ifølge den foreliggende oppfinnelse er den tid som går fra legeringen er på homogeniseringstemperatur, hvor alle de oppløselige bestanddeler enten er i fast oppløsning eller under opp-løsning, til den er avkjølt til 510° C, hvor diffusjonshastigheten for jernholdige partikler blir for langsom til å tillate vesentlig vekst av partikler av utfelte stoffer, tilstrekkelig lang til å tillate de jernholdige, utfelte partikler å danne seg som relativt store partikler. Den samme totale grad av utfelling foreligger enten de utfelte stoffer forekommer som små eller store partikler, og da volumet av en partikkel er propor-sjonalt med tredje potens av diameteren, vil det være klart at en legering vil inne-holde vesentlig færre partikler hvis partik-lene av utfelte stoffer tillates å bli betydelig større. Det er funnet at der er meget mindre lysspredning når der i den anodiske oksydfilm foreligger få store partikler, enn når der foreligger mange små partikler, og en anodisk oksydfilm som inneholder færre og større partikler, vil derfor være klar, varm og dyp selv om den samme mengde utfelte stoffer er tilstede i filmen.
Utførelsen av og fordelene ved den foreliggende oppfinnelse er belyst i de følgende eksempler, hvor fremgangsmåten ifølge oppfinnelsen (eksempel 2) er sammenlignet med den tidligere vanlige fremgangsmåte (eksempel 1).
Eksempel 1:
Over et langt tidsrom ble der støpt og valset ca. 500 partier av en 5005-legering. Metallsammensetningen av disse partier lå innenfor følgende grenser uttrykt i %:
Alle støpeblokker ble homogenisert ved et opphold i 1—3 timer ved 538—552° C og etterfølgende avkjøling i luft til værelsetemperatur, uten noe spesielt herredømme over avkjølingshastigheten, hvoretter blokkene ble overflatehøvlet. For varmvalsing ble de overflatehøvlede blokker påny oppvarmet til 468—510° C i minst én time og valset. Ved kaldvalsing og mellomliggende utglødning varierte fremgangsmåten i over-ensstemmelse med den ønskede endelige utglødning og fulgte stort sett vanlig prak-sis. Etter etsing i en 5 %'s vandig oppløs-ning av kaustisk soda i ti minutter ved 54° C ble prøvestykker av plater fra hvert parti anodisert i et vandig bad som inneholdt 90—100 g/l sulfosalicylsyre og 4,5—5,5 g/l svovelsyre. Temperaturen av badet var 25° C, og anodestrømtettheten ved begynnelsen 258 A/m-. Etter at spenningen over anodi-seringscellen nådde 50 volt, ble anodiserin-gen fortsatt under denne spenning inntil 116 Ah/m<2> hadde passert gjennom platen. De anodiserte plater ble deretter neddykket i tjue minutter ved 91—96° C i et vandig bad som inneholdt 1,0 g/l natruimlignosul-fat og 0,5 g/l nikkelacetat, ved en pH-verdi av 5,0 ± 0,2. Fargen av hver anodisert plate ble målt i henhold til CIE-systemet for fargemåling under anvendelse av en Photo-volt Tristimulus Reflectionmeter Model 610. Refleksjonsfaktoren for grønt lys, som er en angivelse av mørkheten eller lysheten av overflaten, ble målt som den prosentuelle andel av innfallende grønt lys som ble reflektert av overflaten. Gulhetsfaktoren, som fås som ble også målt. Disse målinger skaffer en praktisk fremgangsmåte til sammenligning av fargeforskjeller av gjennomfargede ano-
diserte overflater. De forskjellige partier av plater i dette eksempel viste en refleksjons-
faktor for grønt lys i området fra 12—24 og en gulhetsfaktor i området fra 16—43. For anvendelse av gjennomf arget anodisert aluminium til byggeformål er et område av denne størrelse utilfredsstillende.
Eksempel 2:
Over et langt tidsrom ble ca. 50 partier
av en 5005-legering støpt og valset. Metallsammensetningen av disse partier falt in-
nenfor følgende grenser uttrykt i % :
Alle støpeblokker ble homogenisert
ved opphold i ikke mindre enn 9 timer ved 593—621° C og avkjøling med en gjennom-
snittlig hastighet av 170° C pr. time eller langsommere til 510° C. Støpeblokkene ble deretter luftkjølt til værelsetemperatur og overflatehøvlet. For varmvalsing ble blok-
kene deretter oppvarmet påny til 454—510°
C, holdt på denne temperatur i minst én
time og deretter valset. Kaldvalsing og ut-
glødning ble utført som i eksempel 1. Alle plateprøver fra dette eksempel ble deretter etset, anodisert og tettet som angitt i ek-
sempel 1, hvoretter fargefaktorene ble målt. Refleksjonsfaktoren for grønt lys lå
i området fra 19—27 og gulhetsfaktoren i området fra 22—29. Dette er betydelig min-
dre områder enn i eksempel 1, og dette ma-
teriale er derfor å foretrekke for bygge-
formål.
I tillegg til det snevrere område for
fargen som fås ved anvendelse av mate-
rialet ifølge oppfinnelsen, fås der ytter-
ligere den fordel at de anodiske belegg virker betydelig mer tiltalende og glans-
fulle. Videre ville også gjennomsiktige (clear) anodiske belegg fremstilt ved svovelsyreanodisering av materialet ifølge oppfinnelsen oppvise en lignende tiltalende glans i motsetning til det matte utseende av materialet ifølge eksempel 1 anodisert på tilsvarende måte. Ved forlenget etsing av materialet ifølge oppfinnelsen fulgt av
svovelsyreanodisering kan overflaten dess-
uten bibringes et ønsket hvitt utseende.
En legering som er satt sammen, var-mebehandlet og valset som angitt ovenfor,
har følgende egenskaper. Det er en 5005-
legering med ønskede egenskaper med hen-
syn til styrke og bearbeidbarhet, gode over-flateegenskaper og gode anodiserings-
egenskaper. Legeringen er ikke overdrevet følsom overfor variasjoner i den forutgå-
ende varmebehandling. Det vil si at to blokker som er underkastet en hvilken som helst varmebehandling innenfor området som er karakteristisk for oppfinnelsen, vil oppvise omtrent den samme reaksjon på en farge-anodiseringsbehandling. Et materia-
le som er sammensatt som angitt ovenfor,
er ikke følsomt overfor variasjoner i sam-
mensetning innenfor de angitte grenser.
Det vil si at to blokker som har en sam-
mensetning ifølge oppfinnelsen, vil oppvise omtrent den samme reaksjon på fargeano-diseringsbehandling. De sammensetninger og varmebehandlinger som er angitt oven-
for, binder (lock-in) farge-anodiserings-
reaksjonen av platen, slik at anodiserings-
bedrifter kan stole på fargereaksjonen av en legering de mottar og bare behøver å
konsentrere seg om detaljer ved den elek-
trolytiske anodiseringsoperasjon som de ut-
fører, for å sikre reproduserbare farger i produktet.

Claims (4)

1. Fremgangsmåte til fremstilling av aluminiumplater for farge-anodisering, karakterisert ved at der fremstilles en legering som består av 0,06—0,15 % silisium, 0,45—0,65 % jern, 0,03—010 % kobber, 0—0,07 % mangan, 0,7—0,9 % magnesium, 0,05—0,1 % krom, 0—0,25 % sink, ikke mer enn 0,15 % tilsammen av øvrige bestand-
deler og resten aluminium, og den således sammensatte legering oppvarmes til homogeniseringstemperatur i et tidsrom som er tilstrekkelig til å bringe det meste av de oppløselige bestanddeler i fast oppløsning, hvoretter legeringen avkjøles fra homogeniseringstemperaturen til en temperatur under ca. 510° C med en gjennomsnitts-hastighet av mindre enn 17° C pr. time og den resulterende legering valses til plater.
2. Fremgangsmåten som angitt i påstand 1, karakterisert ved at homogeniseringstemperaturen er ca. 593— 621° C.
3. Fremgangsmåte som angitt i påstand 1 eller 2, karakterisert ved at lege- ringen avkjøles fra 510° C til værelsetemperatur, overflatehøvles og oppvarmes på-ny til en temperatur av ca. 454—510° C, hvoretter den valses til plater.
4. Fremgangsmåte som angitt i påstand 2, karakterisert ved at legeringen holdes på homogeniseringstemperatur i minst 9 timer, at den etter avkjøling til ca. 510° C avkjøles ytterligere til en temperatur under 104°C , og at legeringen deretter oppvarmes påny til en temperatur av ca. 454—510° C og holdes på denne temperatur i minst en time før den valses.
NO831413A 1982-04-22 1983-04-21 Grunnmasse til bruk i et legemiddelfrigivende preparat for syre-stabile polypeptider. NO162368B (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO841544A NO164302C (no) 1982-04-22 1984-04-17 Farmasoeytisk eller veterinaermedisinsk godtagbar amfipatisk ikke-fornettet, lineaer forgrenet eller pode-blokk-kopolymer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8211704 1982-04-22

Publications (2)

Publication Number Publication Date
NO831413L NO831413L (no) 1983-10-24
NO162368B true NO162368B (no) 1989-09-11

Family

ID=10529874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO831413A NO162368B (no) 1982-04-22 1983-04-21 Grunnmasse til bruk i et legemiddelfrigivende preparat for syre-stabile polypeptider.

Country Status (19)

Country Link
US (2) US4526938A (no)
EP (1) EP0092918B1 (no)
JP (2) JPS58191714A (no)
AT (1) ATE37983T1 (no)
AU (1) AU566010B2 (no)
CA (1) CA1246265A (no)
DE (1) DE3378250D1 (no)
DK (1) DK165458C (no)
ES (2) ES521713A0 (no)
FI (1) FI80284C (no)
GR (1) GR78529B (no)
HU (1) HU198093B (no)
IE (1) IE54728B1 (no)
IL (1) IL68426A (no)
NO (1) NO162368B (no)
NZ (1) NZ203970A (no)
PT (1) PT76576B (no)
YU (1) YU44974B (no)
ZA (1) ZA832601B (no)

Families Citing this family (517)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
CH660488A5 (en) * 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
JPS6136321A (ja) * 1984-07-27 1986-02-21 Daicel Chem Ind Ltd 新規なポリマ−およびその樹脂組成物
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
JPH0611709B2 (ja) * 1984-10-19 1994-02-16 チロン コーポレイション 角膜基質創傷の治療のための組成物
US4895724A (en) * 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US5036045A (en) * 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801457A (en) * 1986-08-01 1989-01-31 Sandoz Pharm. Corp. Polyacetal hydrogels formed from divinyl ethers and polyols
US4882168A (en) * 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5688519A (en) * 1987-04-06 1997-11-18 Leonard; Robert J. Flash-flow fused medicinal implants
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5017560A (en) * 1987-11-06 1991-05-21 Pitman-Moore, Inc. Poultry growth promotion
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
JPH01163135A (ja) * 1987-12-18 1989-06-27 Taki Chem Co Ltd 徐放性基剤の製造方法
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US5137669A (en) * 1988-03-02 1992-08-11 Endocon, Inc. Manufacture of partially fused peptide pellet
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JPH064540B2 (ja) * 1988-09-14 1994-01-19 多木化学株式会社 医用組成物
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
WO1990010437A1 (en) * 1989-03-09 1990-09-20 Endocon, Inc. Partially fused peptide pellet
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE59003337D1 (de) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling mit retardierter Wirkstofffreisetzung.
DE3935736A1 (de) * 1989-10-27 1991-05-02 Chemie Linz Deutschland Pressling mit retardierter wirkstofffreisetzung
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5360892A (en) * 1990-06-26 1994-11-01 Arch Development Corporation Water and UV degradable lactic acid polymers
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US6353030B1 (en) 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5861166A (en) * 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
AU1979392A (en) * 1991-05-14 1992-12-30 Endocon, Inc. Engineering the local inflammatory response as a means of controlled release drug delivery
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
FR2678168B1 (fr) 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
EP0596123A4 (en) * 1991-10-31 1995-03-29 Kobe Steel Ltd BIODEGRADABLE PLASTIC MATERIAL.
DE69329594T2 (de) * 1992-02-28 2001-05-31 Univ Texas Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5352515A (en) * 1992-03-02 1994-10-04 American Cyanamid Company Coating for tissue drag reduction
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
KR960015447B1 (ko) * 1993-03-16 1996-11-14 주식회사 삼양사 의료용 생분해성 고분자
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US20050181976A1 (en) * 1993-05-10 2005-08-18 Ekwuribe Nnochiri N. Amphiphilic oligomers
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5522841A (en) * 1993-05-27 1996-06-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
JP3220331B2 (ja) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US5563238A (en) * 1993-08-05 1996-10-08 Arch Development Corporation Water and UV degradable lactic acid polymers
KR0148704B1 (ko) * 1994-01-10 1998-08-17 김상응 생체분해성 약물전달용 고분자
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5527271A (en) * 1994-03-30 1996-06-18 Bristol-Myers Squibb Co. Thermoplastic hydrogel impregnated composite material
KR0141431B1 (ko) * 1994-05-17 1998-07-01 김상웅 생분해성 하이드로겔 고분자
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5714573A (en) * 1995-01-19 1998-02-03 Cargill, Incorporated Impact modified melt-stable lactide polymer compositions and processes for manufacture thereof
US5618850A (en) 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5939157A (en) * 1995-10-30 1999-08-17 Acushnet Company Conforming shoe construction using gels and method of making the same
US5985383A (en) * 1995-03-15 1999-11-16 Acushnet Company Conforming shoe construction and gel compositions therefor
US5955159A (en) * 1995-03-15 1999-09-21 Acushnet Company Conforming shoe construction using gels and method of making the same
JP3145409B2 (ja) 1995-03-24 2001-03-12 フォーカル, インコーポレイテッド 活性酸素阻害剤の制御送達を用いる癒着の低減
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
DE69636006T2 (de) * 1995-06-12 2006-11-23 MicroActive Corp., Reno Transparente biozide zusammensetzungen mit verzögerter freigabe
CA2228118A1 (en) 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5766704A (en) * 1995-10-27 1998-06-16 Acushnet Company Conforming shoe construction and gel compositions therefor
FR2741628B1 (fr) * 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5756651A (en) * 1996-07-17 1998-05-26 Chronopol, Inc. Impact modified polylactide
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
ZA978537B (en) * 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
US6191236B1 (en) 1996-10-11 2001-02-20 United States Surgical Corporation Bioabsorbable suture and method of its manufacture
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6197350B1 (en) * 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
CA2274676A1 (en) 1996-12-31 1998-07-09 James Hongxue Wang Water-responsive polymer compositions and method of making the same
US6402520B1 (en) * 1997-04-30 2002-06-11 Unique Logic And Technology, Inc. Electroencephalograph based biofeedback system for improving learning skills
EP0986402A2 (en) 1997-06-06 2000-03-22 Battelle Memorial Institute Reversible geling co-polymer and method of making
US5945480A (en) * 1997-07-31 1999-08-31 Kimberly-Clark Worldwide, Inc. Water-responsive, biodegradable fibers comprising polylactide modified polylactide and polyvinyl alcohol, and method for making the fibers
US5952433A (en) * 1997-07-31 1999-09-14 Kimberly-Clark Worldwide, Inc. Modified polyactide compositions and a reactive-extrusion process to make the same
US6075118A (en) * 1997-07-31 2000-06-13 Kimberly-Clark Worldwide, Inc. Water-responsive, biodegradable film compositions comprising polylactide and polyvinyl alcohol, and a method for making the films
US6552162B1 (en) 1997-07-31 2003-04-22 Kimberly-Clark Worldwide, Inc. Water-responsive, biodegradable compositions and films and articles comprising a blend of polylactide and polyvinyl alcohol and methods for making the same
CA2299393A1 (en) * 1997-08-08 1999-02-18 Sung Wan Kim Injectable biodegradable block copolymer gels for use in drug delivery
US5852117A (en) * 1997-08-26 1998-12-22 National Starch And Chemical Investment Holding Corporation Process for making lactide graft copolymers
US6007565A (en) * 1997-09-05 1999-12-28 United States Surgical Absorbable block copolymers and surgical articles fabricated therefrom
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6277927B1 (en) 1997-11-26 2001-08-21 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
WO1999047543A2 (en) * 1998-03-18 1999-09-23 University Technology Corporation Sustained-release composition including amorphous polymer
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
ME00867B (me) * 1998-03-19 2008-08-07 Merck Sharp & Dohme Tečne polimerne smeše za kontrolisano oslobađanje bioaktivnih supstanci
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6841617B2 (en) * 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US7087244B2 (en) * 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
US20040228794A1 (en) * 1998-04-10 2004-11-18 Battelle Memorial Institute Therapeutic agent carrier compositions
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6350518B1 (en) 1998-06-01 2002-02-26 Kimberly-Clark Worldwide, Inc. Methods of making blend compositions of an unmodified poly vinyl alcohol and a thermoplastic elastomer
DE69920711D1 (de) * 1998-07-21 2004-11-04 Monsanto Technology Llc Klärung von protein-niederschlagsuspensionen durch verwendung von anionischen polymerischen flockungsmitteln
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
ES2220406T3 (es) * 1999-02-19 2004-12-16 Universiteit Utrecht Hidrogeles estereocomplejos.
JP4548623B2 (ja) * 1999-02-24 2010-09-22 多木化学株式会社 生体材料
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
US6217630B1 (en) 1999-05-03 2001-04-17 Cargill, Incorporated Conditioned fertilizer product, method for conditioning fertilizer, and method for using conditioned fertilizer product
WO2000071602A1 (fr) * 1999-05-19 2000-11-30 Nof Corporation Polymere, materiau degradable in vivo et utilisation
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US7052711B2 (en) * 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
EP1263491A2 (en) * 2000-03-01 2002-12-11 Glaxo Group Limited Metered dose inhaler
US7193007B2 (en) * 2000-03-15 2007-03-20 Yu-Ling Cheng Environment responsive gelling copolymer
US7018645B1 (en) * 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US20040023987A1 (en) * 2000-06-14 2004-02-05 Yoshio Hata Sustained release compositions
AU2001281921A1 (en) * 2000-06-29 2002-01-08 Bernina Biosystems Gmbh Bdellosomes
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
KR100451910B1 (ko) * 2000-10-05 2004-10-08 주식회사 바이오폴리테크 수용성 생체분해성 고분자 겔 및 그의 제조방법
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン,エルエルシー 予防及び治療のために抗rsv抗体を投与/処方する方法
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
DE10111767B4 (de) * 2001-03-12 2005-03-24 Schwarz Pharma Ag Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
WO2003000156A1 (en) * 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
KR20040017297A (ko) * 2001-07-13 2004-02-26 메비올 가부시키가이샤 조직·장기 재생용 재료 및 조직·장기 재생 방법
US7309498B2 (en) * 2001-10-10 2007-12-18 Belenkaya Bronislava G Biodegradable absorbents and methods of preparation
AU2002343681B2 (en) * 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US8323693B2 (en) 2002-03-14 2012-12-04 Medrx Co., Ltd. External preparation for wounds
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
CA2483778A1 (en) * 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US20030228366A1 (en) * 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2494485A1 (en) * 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン,エルエルシー Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
KR101476067B1 (ko) * 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
EP1559440B1 (en) * 2002-10-29 2015-09-23 Toray Industries, Inc. Vascular embolization meterial
US7407672B2 (en) * 2002-11-04 2008-08-05 National Heart Center Composition derived from biological materials and method of use and preparation
AU2003285200A1 (en) * 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1569683B1 (en) 2002-11-26 2010-03-03 Biocon Limited Modified natriuretic compounds, conjugates, and uses thereof
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
EP1596804A4 (en) 2003-01-13 2008-02-06 Macrogenics Inc SOLUBLE FCyR FUSION PROTEINS AND METHODS OF USE
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 il?9 항체 및 그의 용도
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US8465537B2 (en) * 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
US20050013870A1 (en) * 2003-07-17 2005-01-20 Toby Freyman Decellularized extracellular matrix of conditioned body tissues and uses thereof
US7326571B2 (en) * 2003-07-17 2008-02-05 Boston Scientific Scimed, Inc. Decellularized bone marrow extracellular matrix
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US8153591B2 (en) 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
ITMI20031872A1 (it) * 2003-09-30 2005-04-01 Mediolanum Farmaceutici Srl Copolimeri di poliesteri e polivinilpirrolidone.
EP2267062B1 (en) * 2003-11-04 2017-10-25 SupraPolix B.V. Supramolecular polymers containing quadruple hydrogen bonding units in the polymer backbone
US20060053516A1 (en) * 2003-12-05 2006-03-09 The University Of Hong Kong Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS
AU2004296851A1 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
JP2007517042A (ja) * 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはgnrhの制御放出のための、好ましくはpegおよびplgの混合物を含有するポリマーインプラント
KR20050077916A (ko) 2004-01-29 2005-08-04 학교법인 성균관대학 pH 및 온도 민감성 하이드로겔
CN1950429B (zh) * 2004-05-05 2011-08-10 弗门尼舍有限公司 生物可降解接枝共聚物
US20050281866A1 (en) * 2004-05-24 2005-12-22 Genzyme Corporation Adherent polymeric compositions
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US20050271727A1 (en) * 2004-06-07 2005-12-08 Callisyn Pharmaceuticals, Inc. Biodegradable and biocompatible crosslinked polymer hydrogel prepared from PVA and/or PEG macromer mixtures
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP1773903B1 (en) * 2004-07-12 2017-08-09 SupraPolix B.V. Supramolecular ionomers
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
US8357391B2 (en) * 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
US20060149363A1 (en) * 2005-01-06 2006-07-06 Scimed Life Systems, Inc. Optimally expanded, collagen sealed ePTFE graft with improved tissue ingrowth
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン,エルエルシー 抗体のフレームワーク・シャッフル
KR100665672B1 (ko) * 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2367583T3 (es) * 2005-05-04 2011-11-10 Suprapolix B.V. Hidrogeles con enlaces de hidrógeno.
EP1877113B1 (en) 2005-05-04 2011-11-09 SupraPolix B.V. Modular bioresorbable or biomedical, biologically active supramolecular materials
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CN103172737A (zh) * 2005-06-30 2013-06-26 Abbvie公司 Il-12/p40结合蛋白
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US20070078479A1 (en) * 2005-10-04 2007-04-05 Boston Scientific Scimed, Inc. Self-expanding vaso-occlusive devices with regulated expansion
US20070078480A1 (en) * 2005-10-04 2007-04-05 Boston Scientific Scimed, Inc. Self-expanding biodegradable or water-soluble vaso-occlusive devices
JP5398112B2 (ja) * 2005-10-27 2014-01-29 東レ株式会社 生分解性粒子およびその製造方法
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
KR100738083B1 (ko) * 2005-12-20 2007-07-12 삼성전자주식회사 마이크로어레이용 기판 및 그의 제조방법
US8916206B2 (en) 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US20070178137A1 (en) * 2006-02-01 2007-08-02 Toby Freyman Local control of inflammation
US20070239194A1 (en) * 2006-04-05 2007-10-11 Boston Scientific Scimed, Inc. Vaso-occlusive devices having expandable fibers
US20070280986A1 (en) * 2006-06-01 2007-12-06 Carlos Gil Intra-operative coating of implants
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
MY162024A (en) 2006-08-28 2017-05-31 La Jolla Inst Allergy & Immunology Antagonistic human light-specific human monoclonal antibodies
UA115964C2 (uk) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані Інтерлейкін-13-зв'язувальний білок
JP2010504318A (ja) * 2006-09-22 2010-02-12 ラボファーム インコーポレイテッド pH標的化薬剤送達のための組成物及び方法
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
DE602007008125D1 (de) * 2006-10-31 2010-09-09 Surmodics Pharmaceuticals Inc Kugelförmige polymer-teilchen
ATE527305T1 (de) 2006-11-20 2011-10-15 Suprapolix Bv Supramolekulare polymere aus niedrigschmelzenden, leicht verarbeitbaren bausteinen
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
ATE515538T1 (de) 2007-03-23 2011-07-15 Suprapolix Bv Starke umkehrbare hydrogels
US8628789B2 (en) 2007-03-23 2014-01-14 Suprapolix, B.V. Strong reversible hydrogels
KR100838809B1 (ko) * 2007-05-03 2008-06-17 성균관대학교산학협력단 겔강도가 우수한 온도 및 피에치 민감성 블록 공중합체 및이의 제조방법과 이를 이용한 약물전달체
US20100129456A1 (en) 2007-05-14 2010-05-27 Ltt Bio-Pharma Co., Ltd. Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JP5718637B2 (ja) 2007-06-21 2015-05-13 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディおよびその使用
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR100941774B1 (ko) * 2007-09-06 2010-02-11 성균관대학교산학협력단 인체안전성이 우수한 온도 및 피에치 민감성 블록공중합체및 이의 제조방법과 이를 이용한 약물전달체
WO2009086483A2 (en) * 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein particles, particle devices and methods thereof
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2756756B1 (en) 2008-04-28 2016-01-06 Zogenix, Inc. Novel formulations for treatment of migraine
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR101649189B1 (ko) 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(rage)에 대한 항체 및 이의 용도
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2010002262A1 (en) * 2008-07-04 2010-01-07 Suprapolix B.V. High flow supramolecular compounds
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
NZ590074A (en) * 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AU2009270695A1 (en) 2008-07-17 2010-01-21 Ap Pharma Methods for enhancing the stability of polyorthoesters and their formulations
KR100987693B1 (ko) * 2008-10-20 2010-10-13 서울대학교산학협력단 폴리(에틸렌 글리콜)-b-[폴리(L-세린)-g-폴리(D,L-락티드)]의 블록공중합체 및 이를 이용한 약물전달체용 나노입자의 제조 방법
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
TW201031421A (en) * 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之dll4結合蛋白質
IN2012DN02737A (no) * 2009-09-01 2015-09-11 Abbott Lab
MX366955B (es) 2009-09-15 2019-07-31 Bluelink Pharmaceuticals Inc Crlx101 para usarse en el tratamiento de cáncer.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011044368A1 (en) 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496245B1 (en) 2009-11-02 2016-07-20 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
NZ599527A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Fragmented hydrogels
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
EP2503888A4 (en) * 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EP4234698A3 (en) 2010-05-06 2023-11-08 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
EP2571532B1 (en) 2010-05-14 2017-05-03 Abbvie Inc. Il-1 binding proteins
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
JP5964300B2 (ja) 2010-08-02 2016-08-03 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディおよびその使用
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
RS63063B1 (sr) 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
EA036314B1 (ru) 2010-08-20 2020-10-26 Новартис Аг Выделенные антитела к рецептору эпидермального фактора роста-3 (her3) и их фрагменты, фармацевтическая композиция, содержащая эти антитела и фрагменты, и их применение для лечения рака
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5999567B2 (ja) 2010-10-20 2016-09-28 ディーエスエム アイピー アセッツ ビー.ブイ. ペンダント型親水性物質を有する生分解性組成物および関連デバイス
EP2450394B1 (en) 2010-11-05 2017-06-07 SupraPolix B.V. A process for the preparation of a supramolecular polymer
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
CN103249436B (zh) 2010-12-09 2015-09-30 东丽株式会社 生物降解性颗粒、血管栓塞材料及生物降解性颗粒的制造方法
EP2656864B1 (en) 2010-12-20 2016-09-21 Toray Industries, Inc. Biodegradable particles for medical treatment and vascular embolization material
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Il-1結合蛋白
RU2627171C2 (ru) 2010-12-21 2017-08-03 Эббви Инк. Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
PT2658525T (pt) 2010-12-29 2017-11-30 Medincell Composições biodegradáveis de entrega de fármaco
CN103442742B (zh) 2011-03-30 2016-08-10 东丽株式会社 生物降解性粒子、血管栓塞材料及生物降解性粒子的制造方法
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス,インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
CN103608424B (zh) 2011-06-30 2015-11-25 圣戈班磨料磨具有限公司 涂覆的磨料聚集体和包含其的产品
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
SG10201504605RA (en) 2011-09-23 2015-07-30 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof
RU2014120981A (ru) 2011-10-24 2015-12-10 Эббви Инк. Иммунные связывающие агенты против склеростина
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
EA036739B1 (ru) 2011-12-05 2020-12-15 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3)
US9636398B2 (en) 2011-12-14 2017-05-02 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791173B1 (en) 2011-12-14 2020-07-29 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
KR20130090950A (ko) 2012-02-07 2013-08-16 성균관대학교산학협력단 듀얼 전이 고분자 하이드로젤 및 이의 이용
US10179173B2 (en) * 2012-03-23 2019-01-15 Regents Of The University Of Minnesota Semi-solid delivery systems
CA2866281C (en) 2012-03-28 2016-11-01 Toray Industries, Inc. Biodegradable material and method for producing biodegradable material
US9504768B2 (en) 2012-03-28 2016-11-29 Toray Industries, Inc. Biodegradable material and method of producing biodegradable material
JP6321633B2 (ja) 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
CA2896091C (en) 2012-12-21 2018-06-19 Amplimmune, Inc. Anti-h7cr antibodies
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
PT2953976T (pt) 2013-02-08 2021-06-23 Novartis Ag Sítios específicos de modificação de anticorpos para preparar imunoconjugados
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3916103A1 (en) 2013-03-14 2021-12-01 Abbott Laboratories Hcv core lipid binding domain monoclonal antibodies
BR112015023355A8 (pt) 2013-03-14 2018-01-30 Abbott Lab antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
CA2906421C (en) 2013-03-14 2022-08-16 George J. Dawson Hcv antigen-antibody combination assay and methods and compositions for use therein
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
JP6682426B2 (ja) 2013-05-24 2020-04-15 メディミューン,エルエルシー 抗b7−h5抗体およびその使用
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
WO2015058868A1 (en) 2013-10-25 2015-04-30 Pangaea Biotech, S.L. Compositions and methods for the treatment of cancer
GB201318990D0 (en) 2013-10-28 2013-12-11 Omg Plc Optical sighting
CA3056647A1 (en) 2013-11-13 2015-05-21 Robert ARCH Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015084883A2 (en) 2013-12-02 2015-06-11 Abbvie, Inc. Compositions and methods for treating osteoarthritis
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
LT3097122T (lt) 2014-01-24 2020-07-27 Ngm Biopharmaceuticals, Inc. Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai
CN106604740A (zh) 2014-02-14 2017-04-26 宏观基因有限公司 用于治疗血管化癌症的改进的方法
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
MX2016011627A (es) 2014-03-12 2016-11-29 Novartis Ag Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
EP3148580B1 (en) 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3169708B1 (en) 2014-07-16 2019-03-20 Dana-Farber Cancer Institute Inc. et Al. Her3 inhibition in low-grade serous ovarian cancers
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
ES2926062T3 (es) 2014-12-09 2022-10-21 Sweetwater Energy Inc Pretratamiento rápido
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
CN104479157B (zh) * 2015-01-06 2017-07-11 山东理工大学 一种聚己内酯与聚乙二醇改进聚肽膜亲水性与柔顺性的方法
US20160244520A1 (en) 2015-01-24 2016-08-25 Abbvie Inc. Compositions and methods for treating psoriatic arthritis
US10501552B2 (en) 2015-01-26 2019-12-10 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
PT3328419T (pt) 2015-07-30 2021-11-26 Macrogenics Inc Moléculas de ligação pd-1 e métodos de utilização
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
EP3365369A1 (en) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
EP3370694A1 (en) 2015-11-06 2018-09-12 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
PT3377041T (pt) 2015-11-16 2023-12-15 Maria Pereira Da Cruz Alves Garcia Método para morcelação e/ou direcionamento de princípios farmaceuticamente ativos ao tecido sinovial
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
SG11201804839WA (en) 2015-12-14 2018-07-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗cd98抗体及び抗体薬物コンジュゲート
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP3835322A3 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3583223A4 (en) 2017-02-16 2020-12-23 Sweetwater Energy, Inc. HIGH PRESSURE ZONES FOR PRE-TREATMENT
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2019108639A1 (en) 2017-12-01 2019-06-06 Pfizer Inc. Anti-cxcr5 antibodies and compositions and uses thereof
CA3083363A1 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
AU2019234213A1 (en) 2018-03-12 2020-09-03 Zoetis Services Llc Anti-NGF antibodies and methods thereof
EP3774863A1 (en) 2018-03-29 2021-02-17 Pfizer Inc Lfa3 variants and compositions and uses thereof
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
WO2019229699A1 (en) 2018-05-31 2019-12-05 Novartis Ag Hepatitis b antibodies
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
AU2019306165A1 (en) 2018-07-20 2021-02-25 Pierre Fabre Medicament Receptor for vista
PE20211605A1 (es) 2018-09-07 2021-08-23 Pfizer ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗TNF-α抗體
JP2022515760A (ja) 2018-12-21 2022-02-22 ノバルティス アーゲー Pmel17に対する抗体及びその結合体
AU2020234394B2 (en) 2019-03-08 2024-02-15 AbTis Co., Ltd. Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof
TW202102526A (zh) 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
EP4004214A1 (en) 2019-07-26 2022-06-01 RegenxBio Inc. Engineered nucleic acid regulatory element and methods of uses thereof
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
CN110615829B (zh) * 2019-09-29 2022-07-19 深圳市三浦天然化妆品有限公司 一种自组装抗菌肽水凝胶
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
WO2021133733A1 (en) 2019-12-22 2021-07-01 Sweetwater Energy, Inc. Methods of making specialized lignin and lignin products from biomass
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP2023523760A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 免疫グロブリン変異体
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022076750A2 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Recombinant adeno-associated viruses for cns or muscle delivery
EP4225777A2 (en) 2020-10-07 2023-08-16 RegenxBio Inc. Adeno-associated viruses for ocular delivery of gene therapy
EP4240494A1 (en) 2020-11-06 2023-09-13 Novartis AG Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ, インコーポレイテッド 高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
GB202103785D0 (en) * 2021-03-18 2021-05-05 UCB Biopharma SRL Formulations
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
CN113354800A (zh) * 2021-06-22 2021-09-07 山东谷雨春生物科技有限公司 一种peg嵌段聚乙丙交酯及其应用
WO2023060272A2 (en) 2021-10-07 2023-04-13 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
WO2023060269A1 (en) 2021-10-07 2023-04-13 Regenxbio Inc. Recombinant adeno-associated viruses for targeted delivery
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
WO2023077092A1 (en) 2021-10-28 2023-05-04 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023152633A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
TW202346590A (zh) 2022-03-13 2023-12-01 美商銳進科斯生物股份有限公司 經修飾之肌肉特異性啟動子
WO2023201277A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
WO2023201308A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024028732A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Cd98 binding constructs for treating brain tumors
WO2024028731A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2024044725A2 (en) 2022-08-24 2024-02-29 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024081746A2 (en) 2022-10-11 2024-04-18 Regenxbio Inc. Engineered nucleic acid regulatory elements and methods and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3922239A (en) * 1971-05-06 1975-11-25 Union Carbide Corp Cellulose esters or ethers blended with cyclic ester polymers
JPS5416979B2 (no) * 1972-01-08 1979-06-26
JPS4884193A (no) * 1972-02-14 1973-11-08
JPS5039795A (no) * 1973-08-07 1975-04-12
US4045418A (en) * 1975-01-28 1977-08-30 Gulf Oil Corporation Copolymers of D,L-lactide and epsilon caprolactone
GB1551620A (en) * 1976-12-13 1979-08-30 Ici Ltd Delivery means for biologically active agents
US4243775A (en) * 1978-11-13 1981-01-06 American Cyanamid Company Synthetic polyester surgical articles
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
CA1123984A (en) * 1977-11-16 1982-05-18 Yuzi Okuzumi Block copolymers of lactide and glycolide and surgical prosthesis therefrom
EP0007731A3 (en) * 1978-07-28 1980-02-20 Imperial Chemical Industries Plc Process for the production of dispersions of hydrophobic particulate solids (e.g. pesticides) and the particulate dispersions thus obtained
FR2439003A1 (fr) * 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
JPS5898329A (ja) * 1981-12-07 1983-06-11 Mitsui Toatsu Chem Inc 粉末または顆粒状ポリグリコ−ル酸の製造方法
US4429080A (en) * 1982-07-01 1984-01-31 American Cyanamid Company Synthetic copolymer surgical articles and method of manufacturing the same

Also Published As

Publication number Publication date
EP0092918A3 (en) 1985-01-16
FI80284C (fi) 1990-05-10
DK178583D0 (da) 1983-04-22
PT76576B (en) 1985-12-16
GR78529B (no) 1984-09-27
NO831413L (no) 1983-10-24
PT76576A (en) 1983-05-01
AU1328083A (en) 1983-10-27
US4942035A (en) 1990-07-17
FI80284B (fi) 1990-01-31
ATE37983T1 (de) 1988-11-15
IE54728B1 (en) 1990-01-17
NZ203970A (en) 1986-04-11
DK178583A (da) 1983-10-23
JPH0788312B2 (ja) 1995-09-27
US4526938A (en) 1985-07-02
JPH0517245B2 (no) 1993-03-08
EP0092918B1 (en) 1988-10-19
ES8501779A1 (es) 1984-12-01
DE3378250D1 (en) 1988-11-24
ZA832601B (en) 1984-02-29
CA1246265A (en) 1988-12-06
JPH04210928A (ja) 1992-08-03
JPS58191714A (ja) 1983-11-09
FI831368L (fi) 1983-10-23
YU44974B (en) 1991-06-30
AU566010B2 (en) 1987-10-08
IL68426A (en) 1986-08-31
FI831368A0 (fi) 1983-04-21
ES8602858A1 (es) 1985-12-01
DK165458C (da) 1993-04-13
EP0092918A2 (en) 1983-11-02
YU89683A (en) 1986-04-30
ES535112A0 (es) 1985-12-01
IE830781L (en) 1983-10-22
ES521713A0 (es) 1984-12-01
DK165458B (da) 1992-11-30
HU198093B (en) 1989-07-28

Similar Documents

Publication Publication Date Title
NO162368B (no) Grunnmasse til bruk i et legemiddelfrigivende preparat for syre-stabile polypeptider.
US20060260947A1 (en) Color Stabilization of Anodized Aluminum Alloys
NO161517B (no) Anordning for aa gi oppdrift til i det minste ett element av et undervannsproduksjonsstigeroer.
JPH04110493A (ja) 赤外線放射用部材およびその製造方法
NO319859B1 (no) Fremgangsmate ved fremstilling av reflektor for lystekniske formal
NO121075B (no)
WO2004063405A3 (en) Magnesium containing aluminum alloys and anodizing process
US3164494A (en) Bright finished aluminum alloy system
US3379580A (en) Method of heat treating and forming an aluminum sheet
US3187428A (en) Method of treating aluminum and aluminum alloys preparatory to bright finishing
CN109642300B (zh) 暗灰色的阳极化铝
US4897316A (en) Plated steel sheet for cans
JP2606469B2 (ja) 自然発色用アルミニウム合金及びその製造方法
US20210087656A1 (en) Cosmetic aluminum alloys made from recycled aluminum scrap
US3280013A (en) Anodizing electrolyte and process
TWI741186B (zh) 鋁積層體及其製造方法
US3098724A (en) Aluminous metal article
US4915798A (en) Corrosion resistant aluminum product with uniformly grey, light-fast surface and process for its manufacture
JPH0372049A (ja) フッ素樹脂塗装、陽極酸化処理用アルミニウム合金板とその製造方法
JPS6039759B2 (ja) アルミニウム合金材の表面処理方法
BRPI0902046A2 (pt) liga, chapa litográfica, e, método para processar uma chapa litográfica
JPH0739622B2 (ja) 陽極酸化処理後の色調が白色のアルミニウム合金板の製造方法
US3175963A (en) Anodized aluminum
JPH02122047A (ja) 耐食性アルミ合金と均一灰色非褪色性表面を有するその製品、並びにその製造方法
KR910008148B1 (ko) 내식성 알루미늄 합금과 이로부터 제조되는 회색의 내광성 표면을 갖는 제품 및 그 제조방법

Legal Events

Date Code Title Description
MK1K Patent expired

Free format text: EXPIRED IN APRIL 2003